{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2017-D-0085\" sorted by posted_date descending", "rows": [["FDA-2017-D-0085-0051", "FDA", "FDA-2017-D-0085", "Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals", "Notice", "Notice of Approval", "2023-02-14T05:00:00Z", 2023, 2, "2023-02-14T05:00:00Z", null, "2023-02-14T15:00:41Z", "2023-03073", 0, 0, "090000648569352e"], ["FDA-2017-D-0085-0044", "FDA", "FDA-2017-D-0085", "Best Practices for Convening a GRAS Panel; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-22T05:00:00Z", 2022, 12, "2022-12-22T05:00:00Z", null, "2022-12-22T14:39:30Z", "2022-27714", 0, 0, "090000648554882e"], ["FDA-2017-D-0085-0045", "FDA", "FDA-2017-D-0085", "Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Other", "Guidance", "2022-12-21T05:00:00Z", 2022, 12, "2022-12-21T05:00:00Z", null, "2024-11-12T23:49:43Z", null, 1, 0, "0900006485549dab"], ["FDA-2017-D-0085-0048", "FDA", "FDA-2017-D-0085", "Reference-30-GRAS Notices Search Results Common Use In Food - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Supporting & Related Material", "Background Material", "2022-12-21T05:00:00Z", 2022, 12, null, null, "2022-12-21T21:13:51Z", null, 0, 0, "0900006485549f5d"], ["FDA-2017-D-0085-0046", "FDA", "FDA-2017-D-0085", "Final Guidance - Reference List - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Supporting & Related Material", "Background Material", "2022-12-21T05:00:00Z", 2022, 12, null, null, "2022-12-21T21:13:02Z", null, 0, 0, "09000064855494a0"], ["FDA-2017-D-0085-0047", "FDA", "FDA-2017-D-0085", "Reference-29-Memorandum-November 4, 2010-Linda Kahl - Substances that Are Generally Recognized as Safe (GRAS); Experience with GRAS Notices - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Supporting & Related Material", "Background Material", "2022-12-21T05:00:00Z", 2022, 12, null, null, "2022-12-21T21:13:35Z", null, 0, 0, "09000064855494a1"], ["FDA-2017-D-0085-0049", "FDA", "FDA-2017-D-0085", "Reference-31-OECD 2017-Guidance on Grouping of Chemicals- Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Supporting & Related Material", "Background Material", "2022-12-21T05:00:00Z", 2022, 12, null, null, "2022-12-21T21:14:18Z", null, 0, 0, "0900006485549f5e"], ["FDA-2017-D-0085-0050", "FDA", "FDA-2017-D-0085", "Reference-32-Ball 2016-Toward Good Read-Across Practice (GRAP) Guidance- Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance", "Supporting & Related Material", "Background Material", "2022-12-21T05:00:00Z", 2022, 12, null, null, "2022-12-21T21:14:43Z", null, 0, 0, "0900006485549f5f"], ["FDA-2017-D-0085-0042", "FDA", "FDA-2017-D-0085", "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Generally Recognized as Safe: Best Practices for Convening a Generally\nRecognized as Safe Panel", "Notice", "30 Day Proposed Information Collection", "2022-10-27T04:00:00Z", 2022, 10, "2022-10-27T04:00:00Z", "2022-11-29T04:59:59Z", "2022-12-21T16:18:56Z", "2022-23378", 0, 0, "0900006485462764"], ["FDA-2017-D-0085-0017", "FDA", "FDA-2017-D-0085", "Reference-16-Milch-2009-From-individual-preference-construction-group-decisions-framing-effects-group-processes re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:27Z", null, 0, 0, "0900006482cb21a1"], ["FDA-2017-D-0085-0023", "FDA", "FDA-2017-D-0085", "Reference-23-About-FEMA-GRAS-Program re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:58Z", null, 0, 0, "0900006482cb21aa"], ["FDA-2017-D-0085-0028", "FDA", "FDA-2017-D-0085", "Reference-28-Pew-2013-Draft-COI-Guidance-Consideration-FDA re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:58:20Z", null, 0, 0, "0900006482cb21af"], ["FDA-2017-D-0085-0003", "FDA", "FDA-2017-D-0085", "GUIDANCE -REFERENCE LIST  re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:17Z", null, 0, 0, "0900006482cb1e6f"], ["FDA-2017-D-0085-0018", "FDA", "FDA-2017-D-0085", "Reference-17-Jonas-2001-Confirmation-bias-sequential-information-search-after-preliminary-decisions re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:32Z", null, 0, 0, "0900006482cb21a2"], ["FDA-2017-D-0085-0026", "FDA", "FDA-2017-D-0085", "Reference-26-Guyatt-2010-Vexing-problem-guidelines-conflicts-interest-potential-solution re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:58:11Z", null, 0, 0, "0900006482cb21ad"], ["FDA-2017-D-0085-0025", "FDA", "FDA-2017-D-0085", "Reference-25-Norris-2011-Conflict-interest-clinical-practice-guideline-development-systematic-review re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:58:07Z", null, 0, 0, "0900006482cb21ac"], ["FDA-2017-D-0085-0011", "FDA", "FDA-2017-D-0085", "Reference-10-IOM-2009-Conflict-Interest-Medical-Research-Education-Practice re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:58Z", null, 0, 0, "0900006482cb219b"], ["FDA-2017-D-0085-0016", "FDA", "FDA-2017-D-0085", "Reference-15-Cheng-Chiou-2008-Framing-effects-group-investment-decision-making-role-group-polarization re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:22Z", null, 0, 0, "0900006482cb21a0"], ["FDA-2017-D-0085-0019", "FDA", "FDA-2017-D-0085", "Reference-18- Mancuso-2014-Effects-cognitive-biases-distributed-team-decision-making re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:37Z", null, 0, 0, "0900006482cb21a3"], ["FDA-2017-D-0085-0024", "FDA", "FDA-2017-D-0085", "Reference-24-Alpert-2004-ACCF-AHA-Codes-Conduct-Human-Studies-Research re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:58:03Z", null, 0, 0, "0900006482cb21ab"], ["FDA-2017-D-0085-0021", "FDA", "FDA-2017-D-0085", "Reference-20-FDA-2016-Draft-Guidance-Procedures-Evaluating-Appearance-Issues-FDA-Advisory-Committees re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:49Z", null, 0, 0, "0900006482cb21a8"], ["FDA-2017-D-0085-0007", "FDA", "FDA-2017-D-0085", "Reference-06-Croskerry-2002-Achieving-quality-clinical-decision-making-cognitive-strategies-detection-bias re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:40Z", null, 0, 0, "0900006482cb1e73"], ["FDA-2017-D-0085-0005", "FDA", "FDA-2017-D-0085", "Reference-02-Guidance-Frequently-Asked-Questions-About-GRAS re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:28Z", null, 0, 0, "0900006482cb1e71"], ["FDA-2017-D-0085-0012", "FDA", "FDA-2017-D-0085", "Reference-11 NAS-2013-Policy-Committee-Composition-Balance-Conflicts-Interest re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:03Z", null, 0, 0, "0900006482cb219c"], ["FDA-2017-D-0085-0006", "FDA", "FDA-2017-D-0085", "Reference-03-Report-Congressional-Requestors-Food-Safety-FDA-Should-Strengthen-Oversight-GRAS-Ingredients re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:35Z", null, 0, 0, "0900006482cb1e72"], ["FDA-2017-D-0085-0009", "FDA", "FDA-2017-D-0085", "Reference-08-Bazerman-2002-Why-good-accountants-do-bad-audits re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:49Z", null, 0, 0, "0900006482cb1e75"], ["FDA-2017-D-0085-0027", "FDA", "FDA-2017-D-0085", "Reference-27-NCCN-2014-NCCN-Disclosure-Policies-Potential-Conflicts-Interest re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:58:16Z", null, 0, 0, "0900006482cb21ae"], ["FDA-2017-D-0085-0022", "FDA", "FDA-2017-D-0085", "Reference-21-FDA-2014-Guidance-Public-Availability-Advisory-Committee-Members-Financial-Interest-Information-Waivers re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:54Z", null, 0, 0, "0900006482cb21a9"], ["FDA-2017-D-0085-0014", "FDA", "FDA-2017-D-0085", "Reference-13-van-Ginkel-van-Knippenberg-2012-Group-leadership-shared-task-representations-decision-making-groups re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:13Z", null, 0, 0, "0900006482cb219e"], ["FDA-2017-D-0085-0013", "FDA", "FDA-2017-D-0085", "Reference-12-Pagliari-2001-Potential-influence-small-group-processes-guideline-development re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:07Z", null, 0, 0, "0900006482cb219d"], ["FDA-2017-D-0085-0004", "FDA", "FDA-2017-D-0085", "Reference-01-Guidance-Regulatory-Framework-GRAS-Substances re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:22Z", null, 0, 0, "0900006482cb1e70"], ["FDA-2017-D-0085-0010", "FDA", "FDA-2017-D-0085", "Reference-09-Moore-2010-Conflict-of-interest-intrusion-bias re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:53Z", null, 0, 0, "0900006482cb219a"], ["FDA-2017-D-0085-0008", "FDA", "FDA-2017-D-0085", "Reference-07-Arnott-2006-Cognitive-biases-decision-support-systems-development re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:56:45Z", null, 0, 0, "0900006482cb1e74"], ["FDA-2017-D-0085-0015", "FDA", "FDA-2017-D-0085", "Reference-14-Tschan-2009-Explicit-reasoning-confirmation-bias-illusory-transactive-memory re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:18Z", null, 0, 0, "0900006482cb219f"], ["FDA-2017-D-0085-0020", "FDA", "FDA-2017-D-0085", "Reference- 19-FDA-2008-Guidance-Procedures-Determining-Conflict-Interest-Eligibility-Participation-FDA-Advisory-Committees re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance", "Supporting & Related Material", "Background Material", "2017-11-27T05:00:00Z", 2017, 11, null, null, "2017-11-27T21:57:44Z", null, 0, 0, "0900006482cb21a7"], ["FDA-2017-D-0085-0001", "FDA", "FDA-2017-D-0085", "Guidance: Best Practices for Convening a Generally Recognized as Safe Panel", "Notice", "Notice of Availability", "2017-11-16T05:00:00Z", 2017, 11, "2017-11-16T05:00:00Z", "2018-05-16T03:59:59Z", "2018-02-08T02:03:44Z", "2017-24845", 0, 0, "0900006482c83776"], ["FDA-2017-D-0085-0002", "FDA", "FDA-2017-D-0085", "Best Practices for Convening a GRAS Panel: Guidance for Industry; Draft Guidance", "Other", "Guidance", "2017-11-16T05:00:00Z", 2017, 11, "2017-11-16T05:00:00Z", null, "2022-12-21T16:44:12Z", null, 0, 0, "0900006482c84b3d"]], "truncated": false, "filtered_table_rows_count": 37, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2017-D-0085"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-D-0085", "results": [{"value": "FDA", "label": "FDA", "count": 37, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-D-0085", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 31, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 4, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-D-0085", "results": [{"value": 2017, "label": 2017, "count": 28, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&posted_year=2017", "selected": false}, {"value": 2022, "label": 2022, "count": 8, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&posted_year=2022", "selected": false}, {"value": 2023, "label": 2023, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&posted_year=2023", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet=comment_start_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-D-0085&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 8.05021298583597, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}